Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

VIGABATRIN

All products: listing conditions apply

Vigabatrin Tablets, USP · PIN 09858318 · 500mg · tablet

Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada brand search: not checked yet (expand to check)

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Vigabatrin Tablets, USP · DIN 09858318 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2023-11-30 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada brand search: not checked yet (expand to check)
Check this DIN again

Vigabatrin Tablets, USP: Formulary list price $5.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858318)

Source record
DIN 09858318: Vigabatrin Tablets, USP Raw flags: sec3c=Y Item: 281200185; group id 451; item number 1124; lccId None; manufacturer id DRR Source form: Tab; strength: 500mg Recorded listing: Temporary benefit (shortage substitute) Source prices (unrounded): $5.0000; ministry $5.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858318 Health Canada brand search: not checked yet (expand to check)
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09858318
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

GABAPENTIN

· 69 products · General benefit (49), Off-Formulary Interchangeable, not an ODB benefit (20) · strengths: 100mg, 300mg, 400mg, 600mg, 800mg · Cap, Tab

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PREGABALIN

· 102 products · General benefit (93), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 25mg, 50mg, 75mg, 150mg, 225mg, 300mg · Cap

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Sabril (vigabatrin) is indicated for:  Treatment of epilepsy only in those patients who respond inadequately to alternative treatment combinations or in whom other drug combinations have not been tolerated and in whom the potential benefits conferred by its use outweigh the risk of ophthalmologic abnormalities (see WARNINGS and PRECAUTIONS, Serious Warnings and Precautions and Ophthalmologic). Sabril is not indicated as a first line antiepileptic treatment. If these criteria are met and the patient and caregiver have been fully apprised of the risk, Sabril can be considered for the adjunctive management of partial epilepsies, with or without secondary generalization, which are not satisfactorily controlled by other antiepilepsy drug combinations.  Management of infantile spasms (IS or West syndrome), as monotherapy, although the benefits of its use and the risks of ophthalmologic abnormalities must be taken into account. While Sabril may be effective initially as monotherapy, clinical experience indicates that at least 50% of patients may require the addition of other antiepileptic drugs owing t… https://pdf.hres.ca/dpd_pm/00059977.PDF PM date: February 9, 2021 Source product: SABRIL; DIN 02065819; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.